Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, School of Medicine, University of California-San Diego, La Jolla, CA, USA.
Otolaryngol Head Neck Surg. 2020 Sep;163(3):546-553. doi: 10.1177/0194599820921401. Epub 2020 May 26.
To identify the dominant clinical factors associated with increased 1-year charges in treating head and neck cancer.
Retrospective review.
Single academic institution.
We retrospectively reviewed 1-year charges for 196 consecutive patients with head and neck cancer (HNC) who were treated exclusively at our institution. We analyzed charges by department as well as factors associated with increased charges per multivariable regression.
The mean age was 59.6 years (SD, 14.9). Most of the population was male (64%), white (70%), and commercially insured (46%). The most common primary sites were the oropharynx (25%; 76%, HPV positive), skin (19%), and thyroid (17%). Eighty-three percent of total charges were due to standard-of-care treatment for HNC: surgery ($16 million), radiation therapy ($22 million), or chemotherapy ($11 million). The median total charge per patient was $212,484 (interquartile range, $78,630-$475,823). Multivariable regression demonstrated that the following were associated with increased charges: nasopharynx subsite ($250,929 [95% CI, $93,290-$408,569]; effect size in US dollars, = .002), advanced stage (American Joint Committee on Cancer, seventh edition; $80,331 [$22,726-$137,936], = .007), therapeutic surgery ($281,893 [$117,371-$446,415], = .001), chemotherapy ($183,331 [$125,497-$241,165], < .001), radiation ($203,397 [$143,454-$263,341], < .001), surgical complication requiring return to the operating room ($147,247 [$37,240-$257,254], = .009), emergency department visits ($89,050 [$23,811-$154,289], = .008), and admissions ($140,894 [$82,895-$198,893], < .001; constant, -$233,927 [-$410,790 to -$57,064]). The top quartile accrued 55% of the total charges.
Radiation, followed by surgery and chemotherapy, were the most expensive components of HNC care. In this analysis, we identified the dominant clinical factors associated with increased charges.
确定与治疗头颈部癌症 1 年费用增加相关的主要临床因素。
回顾性研究。
单一学术机构。
我们回顾性分析了在我们机构接受治疗的 196 例连续头颈部癌症(HNC)患者的 1 年费用。我们按科室分析了费用,并通过多变量回归分析了与费用增加相关的因素。
平均年龄为 59.6 岁(标准差,14.9)。大多数患者为男性(64%)、白人(70%)和商业保险(46%)。最常见的原发部位是口咽(25%;76%HPV 阳性)、皮肤(19%)和甲状腺(17%)。83%的总费用是用于 HNC 的标准治疗:手术(1600 万美元)、放疗(2200 万美元)或化疗(1100 万美元)。每位患者的中位总费用为 212484 美元(四分位距,78630-475823 美元)。多变量回归显示,以下因素与费用增加相关:鼻咽部位(250929 美元[95%置信区间,93290-408569];效应大小, =.002)、晚期(美国癌症联合委员会第 7 版;80331 美元[22726-137936], =.007)、治疗性手术(281893 美元[117371-446415], =.001)、化疗(183331 美元[125497-241165], <.001)、放疗(203397 美元[143454-263341], <.001)、需要返回手术室的手术并发症(147247 美元[37240-257254], =.009)、急诊就诊(89050 美元[23811-154289], =.008)和住院(140894 美元[82895-198893], <.001;常数,-233927 美元[-410790 至-57064])。最高四分位数的患者占总费用的 55%。
放疗、其次是手术和化疗是 HNC 治疗最昂贵的部分。在这项分析中,我们确定了与费用增加相关的主要临床因素。